Semaglutide May Preserve Lean Muscle Better Than Tirzepatide in Weight Loss Trial

Why Does Lean Body Mass Matter During Weight Loss?

When patients lose weight rapidly on GLP-1 receptor agonists, a portion of that loss typically comes from lean tissue, including skeletal muscle. Muscle is metabolically active tissue, meaning it drives resting energy expenditure, supports glucose disposal, and underpins physical function, particularly in older adults. Excessive muscle loss during pharmacological weight reduction has raised concerns among endocrinologists about sarcopenia risk, frailty, and the likelihood of weight regain once therapy is paused.

Clinical guidelines from obesity societies increasingly emphasize body composition — not just scale weight — as the meaningful outcome. Dual-energy X-ray absorptiometry (DEXA) and related imaging now feature in more obesity trials, allowing researchers to distinguish fat mass reduction from lean mass changes. Against that backdrop, differences between leading GLP-1 medications in how they affect muscle preservation have become clinically consequential.

How Do Semaglutide and Tirzepatide Differ Mechanistically?

Semaglutide, marketed by Novo Nordisk as Wegovy for obesity and Ozempic for type 2 diabetes, is a selective GLP-1 receptor agonist. It reduces appetite, slows gastric emptying, and improves glycemic control. Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, is a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, and has generally produced larger absolute weight reductions in head-to-head and network comparisons.

The new comparative analysis reported by Reuters suggests that despite tirzepatide's greater total weight loss, the proportion of that loss coming from lean tissue may be higher than with semaglutide. If confirmed in larger randomized trials, the tradeoff would be meaningful: clinicians may need to balance maximum pounds lost against the quality of weight reduction, particularly in older patients, those with low baseline muscle mass, or patients with sarcopenic obesity.

What Should Patients and Clinicians Do With These Findings?

Regardless of which GLP-1 medication a patient uses, experts consistently recommend pairing pharmacotherapy with resistance training and protein intakes toward the higher end of dietary guidelines to mitigate muscle loss. The American College of Sports Medicine and obesity medicine specialists generally advise at least two resistance training sessions per week during active weight loss phases.

For clinicians, the emerging data underscores the value of individualized prescribing. A younger patient with abundant muscle reserve may tolerate aggressive weight loss on tirzepatide without functional consequence, while an older adult at risk for sarcopenia may benefit from a regimen that prioritizes lean mass preservation. Larger randomized trials with body composition as a primary endpoint will be needed before guidelines formally differentiate the two agents on this basis.